- Current report filing (8-K)
July 22 2009 - 7:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 22, 2009
ONYX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
(State of incorporation)
|
|
0-28298
(Commission File No.)
|
|
94-3154463
(IRS Employer Identification No.)
|
2100 Powell Street
Emeryville, California 94608
(Address of principal executive offices and zip code)
Registrants telephone number, including area code:
(510) 597-6500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 8.01 OTHER EVENTS
On July 22, 2009, Onyx Pharmaceuticals Inc., or Onyx, and Bayer HealthCare Pharmaceuticals, or
Bayer, announced that their first cooperative group-sponsored randomized Phase 2 trial in advanced
metastatic breast cancer met its primary endpoint of progression-free survival. The study
evaluated Nexavar
®
(sorafenib) tablets in combination with the oral chemotherapeutic,
capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study
findings demonstrated that the median progression-free survival was extended in patients treated
with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These
results were statistically significant
(p = .0006). In this trial, the safety and tolerability of
the combination was as expected and did not show any new or unexpected toxicities. A complete data
analysis from this study is expected to be presented at an upcoming scientific meeting.
A copy of the press release, titled Nexavar in Combination with Chemotherapy Shown to Extend
Progression-Free Survival in Patients with Advanced Breast Cancer is attached as Exhibit 99.1
hereto and is incorporated herein by reference.
|
|
|
ITEM 9.01
|
|
FINANCIAL STATEMENTS AND EXHIBITS
|
|
|
|
(d) Exhibits
|
|
|
99.1
|
|
Press release, dated July 22, 2009, titled Nexavar in Combination with Chemotherapy Shown to Extend
Progression-Free Survival in Patients with Advanced Breast Cancer
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Dated: July 22, 2009
|
ONYX PHARMACEUTICALS, INC.
|
|
|
By:
|
/s/ Matthew K. Fust
|
|
|
|
Matthew K. Fust
|
|
|
|
Executive Vice President and Chief
Financial Officer
|
|
|
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Onyx Pharmaceuticals, Inc. (MM) (NASDAQ): 0 recent articles
More News Articles